fbpx

STOCK MARKET NEWS AND ANALYSIS

Author

Andy Pai - page 42

Andy Pai has 251 articles published.

INVESTING IDEAS

Q4 Earnings Preview for AECOM (ACM)

By Andy Pai

AECOM (NYSE:ACM) is scheduled to report Q4 earnings results on November 12, 2019. The company is expected to report earnings of $0.79/share on revenue of $5.243 billion. The consensus earnings per share (EPS) of $0.79/share is based on a poll of 5 analysts and represents a decline of -4.8% over the same quarter last year… Keep Reading

INVESTING IDEAS

Q3 Earnings Preview for Linde plc (LIN)

By Andy Pai

Linde plc (NYSE:LIN) is scheduled to report Q3 earnings results pre-market on November 12, 2019. The company is expected to report earnings of $1.78/share on revenue of $7.155 billion. The consensus earnings per share (EPS) of $1.78/share is based on a poll of 11 analysts and represents a growth of 5.3% over the same quarter… Keep Reading

EARNINGS/INVESTING IDEAS

KEMET (KEM) Q2 Earnings: What To Expect On Monday

By Andy Pai

KEMET Corporation (NYSE:KEM) is scheduled to report Q2 earnings results before trading commences on November 11, 2019. The company is expected to report earnings of $0.65/share on revenue of $325.0 million. The consensus earnings per share (EPS) of $0.65/share is based on a poll of 3 analysts and represents a decline of -25.3% when compared… Keep Reading

INVESTING IDEAS

GrowGeneration Q3 Earnings: Can GRWG Hit Its $0.02 EPS Target?

By Andy Pai

A couple weeks ago, Lake Street Capital initiated coverage of GrowGeneration with a Buy rating and $6.50 price target. Lake Street views the rising demand for cannabis products, creating new opportunities for the company as a supplier of growing equipment. The stock has been soaring this year. GrowGeneration started the year of trading at around… Keep Reading

EARNINGS

FibroGen (FGEN) Q3 Earnings Preview

By Andy Pai

FibroGen, Inc. (NASDAQGS:FGEN) had a rocky week last week when the Nasdaq suspended trading pending the release of news on the company’s Roxadustat safety data in Washington, DC at the American Society of Nephrology Kidney Week. Fortunately for FibroGen, the pooled analyses for Roxadustat Phase III program showed positive efficacy and no increased cardiovascular risk… Keep Reading

1 40 41 42
Go to Top